Evidence Hub

Iron Supplementation and Omega-3 Fatty Acids in Tuberculosis: Friend or Foe?

Wróblewski M, Wróblewska J, Długosz A, Mila-Kierzenkowska C

Biology, 2026

Abstract

Iron supplementation in patients with tuberculosis remains a controversial issue due to the complex role of iron in the host immune response and in the pathogenesis of Mycobacterium tuberculosis infection. Although supplementation may be beneficial for some patients with persistent iron deficiency, the available evidence does not support its routine use. The efficacy and safety of such an intervention appear to depend, among other factors, on the activity of the inflammatory process, the severity of iron metabolism disturbances, and the timing of supplementation initiation. Current evidence highlights the need for an individualized assessment of iron status and for further research to establish clear clinical recommendations. At the same time, growing interest has been directed toward the role of long-chain omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as potential modulators of immune and inflammatory responses in tuberculosis. EPA and DHA may influence immune cell function, cytokine production, and the formation of lipid mediators involved in the resolution of inflammation. Experimental evidence suggests that omega-3 fatty acids may reduce the severity of inflammation and infection-associated anemia; however, their effectiveness may depend on baseline fatty acid status, the stage of disease, and interactions with other nutrients, including iron. Human clinical evidence remains very limited and is currently…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free